ArticleTherapeutic advances in gastroenterology2024

Effectiveness and safety outcomes after long-term (54 weeks) vedolizumab therapy for Crohn's disease: a prospective, real-world observational study including patient-reported outcomes (POLONEZ II).

Ariel Liebert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.